Thromb Haemost 2023; 123(10): 955-965
DOI: 10.1055/s-0043-1769788
DOI: 10.1055/s-0043-1769788
New Technologies, Diagnostic Tools and Drugs
Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A
Authors
-
1 Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
-
2 Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland
-
Ana Patricia Batista Mesquita Sauvage
1 Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland -
3 Biomaterials Laboratory, University Clinics of Dental Medicine, University of Geneva, Switzerland
-
1 Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
-
1 Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
-
1 Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
-
4 Department of Medicine, University of Geneva, Geneva, Switzerland5 Division of Angiology and Hemostasis, University Hospitals of Geneva, Geneva, Switzerland
-
1 Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland